Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New drug combo may reboot treatment for advanced liver cancer

NCT ID NCT07184424

Disease control Sponsor: Beijing Tsinghua Chang Gung Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This study looked at 24 patients with advanced liver cancer whose disease got worse after standard treatment with lenvatinib and an immunotherapy drug. Researchers added a third drug, lenalidomide, to see if it could help control the cancer again. The goal was to measure how long patients lived without their cancer growing and overall survival. This is a small, early study, so results are not yet proven.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lenalidomide
What this could lead to
If it works, this could give doctors a new way to control advanced liver cancer when standard treatments stop working.
What could go wrong
This is a very small, early study with only 24 patients and no comparison group. The results may not apply to everyone, and adding a drug can increase side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

24 people

The number who actually took part.

Started

May 2023

Finished

Apr 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age ≥ 18 years old; * Patients with hepatocellular carcinoma who previously received lenvatinib and PD-1 inhibitors and whose tumors progressed on imaging (enhanced MRI, enhanced CT, or PET-CT) were treated with lenalidomide； * Expected survival period exceeding 3 months; * Patients with a history of other malignant tumors who have been disease-free for more than 2 years after initial treatment (such as non-melanoma skin cancer or cervical carcinoma in situ); * Participants of childbearing age agreed to use contraception during the study period; Exclusion Criteria: * Fibrous plate layer or sarcomatoid HCC or mixed type HCC-ICC; * Currently participating in and receiving other experimental treatments; * Previously underwent solid organ transplantation, diagnosed with immunodeficiency; * Bleeding from esophageal or gastric varices within 3 months prior to enrollment; * Hepatic encephalopathy in the past 6 months, or obvious ascites at enrollment; * Active infection requiring systemic treatment; * CTCAE grading Platelet count \< 50 × 10⁹/L or neutrophil count \< 1 × 10⁹/L * Pregnant or breastfeeding women; * Patients with myocardial ischemia or myocardial infarction graded CTCAE grade II or higher, or uncontrolled arrhythmia; * Patients who have previously used pomalidomide or thalidomide; * Patients who have previously received CTLA-4 in combination with PD-1/PD-L1 inhibitors; * Other situations deemed unsuitable for participation in this trial by researchers;

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HCC - hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HCC - hepatocellular carcinoma

Contacts and locations

Locations

  • Beijing Tsinghua Changgung Hospital

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.